Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cabaletta Bio (CABA)
NASDAQ:CABA
Cabaletta Bio (CABA) Stock Price & Analysis
469 Followers
CABA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.90 - $26.35
Previous Close$7.09
Volume862.73K
Average Volume (3M)1.36M
Market Cap
$342.28M
Enterprise Value$126.60M
Total Cash (Recent Filing)$223.84M
Total Debt (Recent Filing)$8.17M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Aug 08, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding48,276,522
10 Day Avg. Volume2,123,341
30 Day Avg. Volume1,358,446
Standard Deviation0.40
R-Squared0.11
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)1.73
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$36.67Price Target Upside417.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Cabaletta Bio News
PremiumCompany Announcements
Cabaletta Bio’s Promising Clinical Data Advance Autoimmune Therapy
PremiumCompany Announcements
Cabaletta Bio Reveals Insights in Updated Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial CABA-201 Data Look Encouraging and are Tracking In Line with Expectations.
Patient EnrollmentExpanding clinical sites should accelerate patient enrollment; the company now has 12 sites activated, putting it ahead of competitors in the space.
Safety ProfileSafety thus far has been exceptionally clean, with no cases of CRS, ICANS, hypogammaglobulinemia, or infections of any grade.
Bears Say
Clinical Study ResultsThe rheumatoid arthritis study highlights limitations on remission durability and the need for ongoing maintenance therapy.
Market PerformanceCABA has been under pressure, with shares down more than 40% quarter-to-date and over 50% year-to-date due to concerns about increasing competition in the autoimmune cell therapy market.
Operational FocusGiven the limited amount of follow-up, safety will be the primary focus of this initial dataset.
---
Ownership Overview
8.74% Insiders
21.82% Mutual Funds
11.93% Other Institutional Investors
57.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CABA FAQ
What was Cabaletta Bio’s price range in the past 12 months?
Cabaletta Bio lowest stock price was $6.90 and its highest was $26.35 in the past 12 months.
What is Cabaletta Bio’s market cap?
Currently, no data Available
When is Cabaletta Bio’s upcoming earnings report date?
Cabaletta Bio’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Cabaletta Bio’s earnings last quarter?
Cabaletta Bio released its earnings results on May 15, 2024. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.475 by -$0.035.
Is Cabaletta Bio overvalued?
According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued.
Does Cabaletta Bio pay dividends?
Cabaletta Bio does not currently pay dividends.
What is Cabaletta Bio’s EPS estimate?
Cabaletta Bio’s EPS estimate is -$0.55.
How many shares outstanding does Cabaletta Bio have?
Cabaletta Bio has 48,276,524 shares outstanding.
What happened to Cabaletta Bio’s price movement after its last earnings report?
Cabaletta Bio reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.475. Following the earnings report the stock price went up 13.001%.
Which hedge fund is a major shareholder of Cabaletta Bio?
Among the largest hedge funds holding Cabaletta Bio’s share is Perceptive Advisors LLC. It holds Cabaletta Bio’s shares valued at 29M.
---
Cabaletta Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.67 (417.21% Upside)
$36.67 (417.21% Upside)
Blogger Sentiment
Bullish
CABA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 878.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.81%
12-Months-Change
Fundamentals
Return on Equity
-49.06%
Trailing 12-Months
Asset Growth
132.44%
Trailing 12-Months
Company Description
Cabaletta Bio
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
---
CABA Stock 12 Month Forecast
Average Price Target
$36.67
▲(417.21% Upside)
Technical Analysis
Best Analysts Covering CABA
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+185.61%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +185.61% per trade.
---